Dr. Morse on Managing Toxicities and Sequencing Agents in mCRC
February 12th 2018
Michael A. Morse, MD, professor, Medicine, Department of Surgery, Duke University School of Medicine, Duke Cancer Institute, discusses factors that should be taken into consideration when sequencing agents in metastatic colorectal cancer.